Erste Asset Management GmbH Buys 27,652 Shares of Masimo Co. (NASDAQ:MASI)

Erste Asset Management GmbH boosted its stake in Masimo Co. (NASDAQ:MASI - Free Report) by 50.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 82,652 shares of the medical equipment provider's stock after purchasing an additional 27,652 shares during the quarter. Erste Asset Management GmbH owned about 0.15% of Masimo worth $13,934,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of MASI. Smartleaf Asset Management LLC grew its holdings in shares of Masimo by 31.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 60 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 64 shares in the last quarter. Blue Trust Inc. grew its position in Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after purchasing an additional 71 shares in the last quarter. CIBC Asset Management Inc grew its position in Masimo by 5.6% in the 4th quarter. CIBC Asset Management Inc now owns 1,631 shares of the medical equipment provider's stock worth $270,000 after purchasing an additional 87 shares in the last quarter. Finally, MML Investors Services LLC grew its position in Masimo by 4.9% in the 3rd quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider's stock worth $274,000 after purchasing an additional 96 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Piper Sandler upped their price objective on shares of Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Stifel Nicolaus reaffirmed a "buy" rating and issued a $190.00 price objective (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Raymond James boosted their target price on shares of Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research note on Friday, December 27th. Wells Fargo & Company boosted their target price on shares of Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research note on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $194.80.

Insider Activity at Masimo

In other news, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the transaction, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. This represents a 11.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Bilal Muhsin sold 30,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at $4,048,568.28. The trade was a 55.38 % decrease in their position. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by corporate insiders.

Masimo Stock Performance

Shares of MASI stock traded down $4.62 during trading on Tuesday, reaching $168.16. 370,453 shares of the company's stock traded hands, compared to its average volume of 545,039. The company has a market capitalization of $9.07 billion, a P/E ratio of 115.97 and a beta of 1.04. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The firm's 50-day moving average is $174.86 and its 200 day moving average is $158.33. Masimo Co. has a 1 year low of $101.61 and a 1 year high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. The company had revenue of $600.70 million for the quarter, compared to analysts' expectations of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Equities research analysts expect that Masimo Co. will post 4.1 EPS for the current year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.